GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment

Pallavi Madhiraju- August 3, 2024 0

In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary ... Read More

GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma

Pallavi Madhiraju- February 7, 2024 0

GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in the treatment of relapsed or refractory multiple ... Read More

GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

Pallavi Madhiraju- November 28, 2023 0

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More

GSK secures full Jemperli FDA approval for endometrial cancer treatment

Raghuram Kadari- February 14, 2023 0

Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced ... Read More